SNT 25.7% 4.4¢ syntara limited

Ann: FDA Meeting, Business Review Announcement En, page-3

  1. Neo
    2,195 Posts.
    re: Ann: FDA Meeting, Business Review Announc... Primaus,

    Don't forget it's likely going to be a restricted approval, so in the US there is 30,000 patients, however only half are over 18.

    Also remember they could very well now be competing with Vertex for market share/ FDA approval, with Vertex looking to gain approval to treat 50% of the CF population...

 
watchlist Created with Sketch. Add SNT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.